Siemens Healthineers Position on SARS-CoV-2 Serology Testing in the Setting of Vaccination

To enable an effective vaccination strategy, we advocate for the use of accessible, automated, high-throughput SARS-CoV-2 serology testing to help confirm efficacy and promote public health. Siemens Healthineers formulated a position paper based on input from experts in the infectious disease, immunology and vaccine development fields and the currently available body of literature.

Download the full paper here or scan the QR code provided

Siemens Healthineers supports measuring SARS-CoV-2 IgG antibodies in relation to vaccine use for:

An automated and scalable serology assay used for patient care in the context of vaccination should include key technical features for effective use: measurement of spike receptor-binding domain (S1-RBD)-neutralizing IgG antibodies, very high (≥99.5%) specificity, and quantitative results.

Serology tests can inform vaccination utilization and status of vaccine response at multiple junctures:

Appropriate characteristics of a serology assay in the assessment of need to vaccinate and vaccine response:

Contact us for more information!
Shri Devvi Elangovan
Clinical Marketing Specialist, Laboratory Diagnostics
shri.elangovan.ext@siemens-healthineers.com
+60162280540

1Approximately 3-4 weeks after each dose.

2Approximately 3, 6, and 9 months and annually; need to boost

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on telegram
Telegram

Gold Sponsor

This page is sponsored by Siemens Healthineers Sdn Bhd. To learn more about SARS-CoV-2 Serology Testing in the Setting of Vaccination please click the button below.

Contact us for more information!
Shri Devvi Elangovan
Clinical Marketing Specialist, Laboratory Diagnostics
shri.elangovan.ext@siemens-healthineers.com
+60162280540